Amylyx Pharmaceuticals
- Market cap
- 3.44B
- P/E (TTM)i
- -19.45
- P/Bi
- 14.39
- EPSi
- -1.53
- Div yieldi
- 0.00%
- 52W posi
- 55%
Anonymous reader poll. Unscientific, not investment advice.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
- Founded
- 2013
- Employees
- 136
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- amylyx.com
Company profile
- Exchange
- US
- Symbol
- AMLX
- Market-cap rank
- #2392
- Listing date
- 2022-01-07
- Market cap
- 3.44B
- Float cap
- 3.00B
- Shares out
- 125.51M
- Float shares
- 109.55M
Sectors & themes
Quote time 2026-10-08 08:09:13 · For reference only, not investment advice and not tailored to your situation.